Shares of clinical- and commercial-stage biotech Sorrento Therapeutics (NASDAQ: SRNE) plummeted by a whopping 36.8% during the first four trading sessions this week, according to data provided by S&P ...
Three years ago, Sorrento Therapeutics was swatting away a billion dollar offer from private equity, but now the San Diego-based biotech can’t seem to evade the courtroom. The company has filed for ...
SAN DIEGO, July 20, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (SRNEQ) (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat ...
Shares of the commercial-stage biotech Sorrento Therapeutics (NASDAQ: SRNE) are having a strong trading session Tuesday. Specifically, the drugmaker's stock was up by a respectable 6.7%, on average ...
SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, ...
NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) ...
SAN DIEGO, March 17, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (SRNEQ) (OTC: SRNEQ, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat ...
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results